Has Amar Ranawat, MD received payments from drug or device companies?

Yes. Drug and device makers reported $111,597 in general payments to Amar Ranawat, MD across 95 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Amar Ranawat, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Amar Ranawat, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Amar Ranawat, MD

Adult Reconstructive Orthopaedic Surgery · New York, NYNPI 1134131766

Payments from drug & device makers

What this record shows

The money is spread across several categories — consulting fees (57.8%), travel and lodging and food and beverage — rather than concentrated in one kind of arrangement. Linkbio Corp accounts for 65.2% of it on its own, with 18 other manufacturers making up the rest. 2025 is the largest year on record at $54,893, 4.1 times the $13,307 reported in 2019.

$111,597in general payments, 2019–2025

Across 95 payments — averaging $1174.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Linkbio Corp$73K
Arthrex$18K
Medical Device Business Services, Inc.$9K
Heron Therapeutics, Inc.$6K
Innocoll Pharmaceuticals Limited$3K
Globus Medical$1K
plus $4K from 13 others

$14,621in research payments, 2019–2025

Across 4 payments — averaging $3655.31 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Arthrex$15K

What the payments were for

Royalty or licence$830%
Consulting fees$64,52458%
Speaking & faculty fees$2,6002%
Travel & lodging$39,23835%
Food & beverage$5,1525%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Linkbio Corp	31	$72,709
Arthrex	19	$17,609
Medical Device Business Services, Inc.	7	$8,516
Heron Therapeutics, Inc.	6	$5,528
Innocoll Pharmaceuticals Limited	1	$2,600
Globus Medical	4	$1,051
Johnson & Johnson	8	$791
Medshape, Inc.	1	$788
Smith+Nephew	2	$587
Davol Inc.	2	$264
Total Joint Orthopedics, Inc.	1	$219
Pacira Therapeutics, Inc.	1	$148
Amgen	2	$142
Zimmer Biomet	2	$141
Encore Medical, LP	1	$120
Medacta USA, Inc.	1	$110
Orthalign Inc	1	$98
Linvatec Corporation	2	$94
Stryker	3	$83

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

ARTHROPLASTY INSTRUMENTS KNEE ARTHROPLASTY TOTAL KNEE$8,358
ARTHROPLASTY IMPLANTS KNEE & HIP ARTHROPLASTY TOTAL KNEE$4,170
HTX-011$3,475
XARACOLL$2,600
Zynrelef$2,000
Excelsius - GPS$986
ATTUNE$942
DynaNail Helix, Washer, 15 mm$788
Q-FIX$550
RECLAIM$278
ACTIS$255
ARISTA$192
Zilretta$148
EMPHASYS$133
Kincise$133
Accelero-None$123
DJO SURGICAL$120
GMK SPHERE$110

How this compares

$111,597 in reported general payments places this provider in the 80th percentile of 85 adult reconstructive orthopaedic surgery providers in New York.

See all adult reconstructive orthopaedic surgery providers in New York →

Medicare billing

Part B allowed, 2024

$680,247

Medicare patients

903

Services billed

8,145

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Meloxicam	35	$255
Oxycodone Hcl	13	$74

Paid to pharmacies, not to this prescriber.

Other adult reconstructive orthopaedic surgery in New York

Seth JerabekNew York$7.1M
Jose RodriguezNew York$3.4M
Friedrich BoettnerNew York$2.9M
Jonathan VigdorchikNew York$2.3M
William LongNew York$1.5M
Peter SculcoNew York$1.5M
Roshan ShahNew York$1.3M
Herbert CooperNew York$1.3M
Matthew AustinNew York$986K
Patrick MeereNew York$191K

See the full list for New York →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →